CTOs on the Move

QED Therapeutics

www.qedtx.com

 
QED Therapeutics, a subsidiary of BridgeBio Pharma, is a biotechnology company focused on precision medicine for FGFR-driven disorders.
  • Number of Employees: 25-100
  • Annual Revenue: $0-1 Million

Executives

Name Title Contact Details

Funding

QED Therapeutics raised $65M on 01/30/2018

Similar Companies

Chiron

Chiron Corporation was an American multinational biotechnology firm founded in 1981, based in Emeryville, California, that was acquired by Novartis on April 20, 2006.

Liquidia Technologies

Liquidia Technologies is a biopharmaceutical company transforming the development of new therapies by precisely engineering drug particles.

Nile Therapeutics

Nile Therapeutics is a San Mateo, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Canary Medical

Canary Medical was conceived and created by a team of surgeons, medical device developers, and IoT experts with the vision that (1) healthcare transformation requires better and cheaper healthcare data, (2) better monitoring and better data will produce better outcomes at lower costs, and (3) the patient`s own their healthcare data and should be compensated for its use.

Optibrium

Optibrium provides elegant software solutions for small molecule design, optimisation and data analysis. Optibrium`s lead product, StarDrop™, is a comprehensive suite of integrated software with a highly visual and user-friendly interface. StarDrop™ enables a seamless flow from the latest data through to predictive modelling and decision-making regarding the next round of synthesis and research, improving the speed, efficiency, and productivity of the discovery process. The company`s new Augmented Chemistry™ products and services deliver ground-breaking artificial intelligence technologies that continuously learn from all available data to supplement your experience and skills. Founded in 2009, Optibrium is headquartered in Cambridge, UK with offices in Boston and San Francisco, USA. Optibrium continues to develop new products and research novel technologies to improve the efficiency and productivity of the drug discovery process. Optibrium works closely with its broad range of customers and collaborators that include leading global pharma, agrochemical and flavouring companies, biotech and academic groups.